Live Feeds
● TRACKER Updated 29d ago Β· 31 sources tracked

Kodiak skyrockets on positive study data for 2 eye drugs

Kodiak Sciences shared late stage clinical data for Zenkuda, tabirafusp ted, and KSI-101 at the American Academy of Ophthalmology 2026 meeting in New Orleans. Results from the Phase 3 DAYBREAK trial show Zenkuda and tabirafusp ted achieved vision gains non inferior to aflibercept at one year. This performance puts Kodiak in direct competition with an established standard of care. Shares rose between 7.91 percent and 8.56 percent following the data release. The company also presented results from the GLOW2 and Phase 1b APEX trials.

πŸŽ™οΈ

Listen to Live Briefing

Real-time synthesized voice briefing Β· Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (33)
⚑ Key Developments & Real-Time Context
Text size:
  • βœ“ Kodiak Sciences presented clinical data for Zenkuda, tabirafusp ted, and KSI-101 at the American Academy of Ophthalmology 2026 meeting in New Orleans.
  • βœ“ The Phase 3 DAYBREAK trial showed Zenkuda and tabirafusp ted achieved vision gains non inferior to aflibercept at one year.
  • βœ“ Kodiak presented data from the GLOW2 and Phase 1b APEX trials.
πŸ›‘οΈ Source Corroboration: 31 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

The company presented specific results from the DAYBREAK, GLOW2, and APEX trials at the American Academy of Ophthalmology meeting.

Live updates

  1. Kodiak Sciences presents clinical data for Zenkuda and KSI-101 at AAO meeting

    Kodiak Sciences shared late stage clinical data for Zenkuda, tabirafusp ted, and KSI-101 at the American Academy of Ophthalmology 2026 meeting in New Orleans. Results from the Phase 3 DAYBREAK trial show Zenkuda and tabirafusp ted achieved vision gains non inferior to aflibercept at one year. This performance puts Kodiak in direct competition with an established standard of care. Shares rose between 7.91 percent and 8.56 percent following the data release. The company also presented results from the GLOW2 and Phase 1b APEX trials.

    Why it matters

    The company is pursuing a Biologics License Application for Zenkuda across three indications. Success in these trials determines if the drugs can replace or supplement existing treatments for wet age-related macular degeneration.

    What is confirmed

    • Kodiak Sciences presented clinical data for Zenkuda, tabirafusp ted, and KSI-101 at the American Academy of Ophthalmology 2026 meeting in New Orleans.
    • The Phase 3 DAYBREAK trial showed Zenkuda and tabirafusp ted achieved vision gains non inferior to aflibercept at one year.
    • Kodiak presented data from the GLOW2 and Phase 1b APEX trials.

    Still unconfirmed

    • Kodiak Sciences stock traded up by 7.91 percent after promising trial data.
    • Kodiak Sciences shares increased by 8.56 percent following positive results from the Phase 3 DAYBREAK trial.

    What to watch next

    • Submission of the Biologics License Application for Zenkuda
    • Regulatory review of the three indications for Zenkuda
    Sources used for this update (3)
    1. simplywall.st β€” How Investors May Respond To Kodiak Sciences Stock After Wet ...
    2. www.timothysykes.com β€” KOD Stock Explodes As Zenkuda Trial Data Rewire Wall Street
    3. stockanalysis.com β€” Kodiak Sciences (KOD) Stock Price & Overview
    confidence 90%
  2. Kodiak Sciences shares rise on positive Phase 3 eye drug data

    Kodiak Sciences shares increased by 8.56 percent following positive results from the Phase 3 DAYBREAK trial. The study focused on Zenkuda and tabirafusp-ted, meeting primary endpoints for wet age-related macular degeneration while demonstrating favorable safety outcomes. The company intends to submit a Biologics License Application covering three indications for Zenkuda. Investor sentiment remains high as the company prepares to present further data at the American Academy of Ophthalmology Annual Meeting.

    Why it matters

    Positive clinical trial data for ocular treatments can lead to regulatory approval and significant market growth. The success of Zenkuda and tabirafusp-ted suggests a potential new treatment path for macular degeneration.

    What is confirmed

    • Kodiak Sciences shares traded up by 8.56 percent.
    • The Phase 3 DAYBREAK trial met primary endpoints for wet age-related macular degeneration.
    • Kodiak Sciences plans a three-indication Biologics License Application for Zenkuda.

    What to watch next

    • Data presentations at the American Academy of Ophthalmology Annual Meeting
    • Submission of the Biologics License Application for Zenkuda
    Sources used for this update (2)
    1. kodiakcakes.com β€” Oatmeal - Hearty, Wholesome & Protein-Packed - Kodiak
    2. kodiak.aero β€” Kodiak Aircraft - Versatile turboprops for all missions
    confidence 100%
  3. Kodiak Sciences Stock Surges 8.56 Percent on Trial Progress

    Kodiak Sciences shares traded up by 8.56 percent as clinical trial progress and partnership optimism boosted investor sentiment. This upward movement follows previous positive results from the Phase 3 DAYBREAK trial for eye disease candidates Zenkuda and tabirafusp-ted. The earlier study met primary endpoints for wet age-related macular degeneration with favorable safety outcomes. Kodiak previously announced plans for a three-indication Biologics License Application for Zenkuda and upcoming data presentations at the American Academy of Ophthalmology Annual Meeting, sustaining strong market momentum for the company.

    Why it matters

    The recent stock surge reflects ongoing investor enthusiasm for Kodiak Sciences following major clinical developments in its ophthalmology pipeline. Successful trial outcomes for candidates like Zenkuda have previously driven massive share gains and valuation milestones above $100. Market sentiment remains high as the company prepares regulatory submissions and broader data presentations for its therapeutic candidates.

    What is confirmed

    • Kodiak Sciences shares have been trading up by 8.56 percent.

    What to watch next

    • Regulatory filings for the three-indication Biologics License Application for Zenkuda
    • Clinical data presentations at the American Academy of Ophthalmology Annual Meeting
    Sources used for this update (3)
    1. stockstotrade.com β€” KOD Stock Soars As Zenkuda Trial Fuel Sparks Massive Re ...
    2. www.timothysykes.com β€” KOD Stock Rockets As DAYBREAK Trial Rewrites Biotech Expectations
    3. chartexchange.com β€” KOD News | ChartExchange
    confidence 100%
  4. Kodiak Sciences Stock Surges Following Positive Eye Drug Trials

    Kodiak Sciences shares traded above $100 after rising over 600 percent in a year, following successful Phase 3 DAYBREAK trial results for its eye disease candidates. The trial met primary endpoints for Zenkuda and tabirafusp-ted in wet age-related macular degeneration, demonstrating non-inferior vision gains compared to aflibercept alongside favorable safety outcomes. The company plans to submit a three-indication Biologics License Application for Zenkuda covering wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, Kodiak Sciences announced plans to present clinical data for Zenkuda, tabirafusp-ted, and KSI-101 at the American Academy of Ophthalmology Annual Meeting.

    Why it matters

    The company relies on a single long-acting platform intended for application across multiple high-prevalence retinal diseases. This clinical progress follows previous gains where the stock jumped between 120 percent and 178 percent after the initial Phase 3 trial announcement. Investors continue to monitor the precommercial biotech firm closely as it prepares regulatory submissions.

    What is confirmed

    • Kodiak Sciences stock traded below $11 one year and above $100 the next.
    • The Phase 3 DAYBREAK trial in wet age-related macular degeneration met primary endpoints for both Zenkuda and tabirafusp-ted with non-inferior vision gains to aflibercept and favorable safety outcomes.
    • Kodiak Sciences plans to submit a three-indication BLA for Zenkuda in wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.
    • Clinical data across all three late-stage assets, including Zenkuda, tabirafusp-ted, and KSI-101, will be presented at the American Academy of Ophthalmology Annual Meeting.

    What to watch next

    • The upcoming presentations at the American Academy of Ophthalmology Annual Meeting.
    • The formal submission of the three-indication BLA for Zenkuda.
    Sources used for this update (9)
    1. www.biopharmadive.com β€” Clinical Trial News | BioPharma Dive
    2. www.abcmoney.co.uk β€” KOD Stock Surged 600% in a Year β€” Here's Why Biotech ...
    3. simplywall.st β€” Learn Why The Bull Case For Kodiak Sciences Stock Could ...
    4. kodiakcakes.com β€” All Kodiak Products | Flapjacks, Waffles, Snacks & More |...
    5. finance.yahoo.com β€” Kodiak Sciences to Present Clinical Data Across All Three ...
    6. finance.yahoo.com β€” Kodiak Sciences Inc. (KOD)
    7. kodiak.ai β€” Kodiak AI | Autonomous Trucking & AI-Powered Ground Autonomy...
    8. kodiakhistorymuseum.org β€” Kodiak History Museum
    9. www.alaska.org β€” Things To Do In Kodiak | Our Guide To The City's Best Spots
    confidence 100%
  5. Kodiak Sciences stock surges on positive Phase 3 wet AMD trial data

    Kodiak Sciences shares rose between 120% and 178% on September 28 after its Phase 3 DAYBREAK trial met primary endpoints for two eye-disease candidates. Zenkuda (tarcocimab tedromer) and tabirafusp alfa tedromer (KSI-501) demonstrated statistical equivalence to aflibercept, sold as Eylea, in treating treatment-naive patients with wet age-related macular degeneration. Zenkuda achieved an average vision improvement of 7.2 letters compared to 7.6 for Eylea. The company now plans to seek regulatory approval for Zenkuda this year, adding more than $3 billion to its market value.

    Why it matters

    The results resurrect a drug Kodiak had shelved in 2023 following a cataract safety signal. These candidates compete directly with Regeneron's Eylea in the retinal disease market. The company currently generates no revenue and faces significant cash-burn risks.

    What is confirmed

    • Zenkuda and tabirafusp alfa tedromer met primary endpoints in the Phase 3 DAYBREAK trial for wet age-related macular degeneration.
    • Both experimental drugs matched Eylea on vision improvement at one year.
    • Zenkuda showed an average vision improvement of 7.2 letters compared to 7.6 letters for Eylea.
    • Kodiak Sciences shares increased sharply on September 28, with reports of gains ranging from 120% to 178%.
    • The company intends to seek regulatory approval for Zenkuda this year.

    Still unconfirmed

    • A share offering is likely for the cash-burning biotech.
    • The positive findings added more than $3 billion to the company's market value.

    What to watch next

    • FDA filing for Zenkuda
    • Official BLA submission date
    • Company announcement regarding financing or share offerings
    Sources used for this update (27)
    1. biopharmadive.com β€” Kodiak skyrockets on positive study data for 2 eye drugs
    2. Forbes β€” Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial
    3. Fierce Biotech β€” Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3
    4. Yahoo Finance β€” Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
    5. Investor's Business Daily β€” Why This Regeneron Eye Rival Just Catapulted More Than 120%
    6. FirstWord β€” Kodiak surges on Phase III victory for Eylea rival in wet AMD
    7. finance.yahoo.com β€” Why Kodiak Sciences Skyrocketed Today
    8. www.fiercebiotech.com β€” Kodiak's stock doubles as resurrected eye disease drug ...
    9. www.biospace.com β€” Kodiak Sciences’ stock soars 166% after 2 assets ... - BioSpace
    10. finance.yahoo.com β€” Kodiak skyrockets on positive study data for 2 eye drugs
    11. www.talk.bio β€” Kodiak stock surges after two eye-drug candidates match Eylea ...
    12. www.marketbeat.com β€” KOD News Today | Why did Kodiak Sciences stock go up today? $KOD
    confidence 95%
πŸ“Š

Community Sentiment: How do you assess this situation?

Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community